At week 52, patients receiving Aimovig 70 mg or 140 mg from week 24 onward had an average of 4.2 and 4.6 fewer MMD, respectively, compared to study baseline (8.3 MMD). They also continued to ...
THOUSAND OAKS, Calif., Nov. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE ...
PHILADELPHIA — Aimovig, the monthly self-injectable, FDA-approved treatment for preventing migraines, had limited benefits in some patients but favorable responses in others, according to abstracts ...
Novartis has presented new data showing Aimovig cuts acute migraine medication days by half in patients who have failed prior preventive therapies. The results from the STRIVE trial are good news for ...
Basel, April 16, 2020 — Novartis today announced that clinical data for Aimovig® (erenumab) was reported in Neurology. The data strengthens the role Aimovig as a preventive migraine treatment and ...
Amgen Inc. AMGN has announced full results from the phase IIIb study on its anti-CGRP receptor antibody, Aimovig (erenumab), which once again demonstrates a significant reduction in migraine frequency ...
According to Amgen and Novartis, their calcitonin gene-related peptide inhibitor has demonstrated safety and efficacy in a 1-year study in chronic migraine and reinforced safety and tolerability in a ...
The digital press release with multimedia content can be accessed here: Basel, May 17, 2018 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Aimovig TM (erenumab) ...
Amgen and Novartis are set to commercially launch the first calcitonin gene-related peptide (CGRP) receptor inhibitor in the U.S. next week following FDA approval yesterday of the companies’ ...
Novartis AG (ADR) (NVS) today announced that it has received the necessary approval from the U.S. Food and Drug Administration (FDA) for its key drug Aimovig (erenumab) as a preventive treatment of ...
Aimovig monotherapy demonstrated sustained efficacy up to 64 weeks among patients with episodic migraine who were unsuccessfully treated with multiple other preventive therapies, according to study ...
The first randomized, double blind, head-to-head study of Aimovig ® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback